National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

levonorgestrel-releasing intrauterine system
A long-acting, hormone-releasing, intrauterine device consisting of a small, T-shaped, polyethylene frame and a reservoired synthetic progesterone with progestational and potential antineoplastic activities. After insertion of this system into the uterus, the device slowly and gradually releases the hormone. Levonorgestrel acts by binding to the progesterone receptor in the nuclei of target cells, resulting in transcription activation and an alteration in protein synthesis. Subsequently, luteinizing hormone (LH) activity and ovulation are suppressed. Levonorgestrel may also exhibit antiproliferative activity in endometrial tissue. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

US brand name:Mirena
Acronym:LNG-IUS



Previous:levocarnitine, levodopa, levofloxacin, levonantradol, levonorgestrel
Next:Levopa, levothyroxine sodium, Levoxyl, Levulan, Lexapro

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov